PHARMASCROLL
enquiry@pharmascroll.com Mail Us
  • Home
  • About Us
    • Mission and Vision
    • Our Team
    • Why PharmaScroll
  • Business Intelligence
    • TreasureTell
  • Social Media Analytics
    • SocialBI
  • Market Research Services
  • Newsroom
    • Blog
    • Press Release
    • Recent News
      • Neuroscience
        • Migraine
        • Multiple Sclerosis
        • Alzheimer’s
        • Parkinson’s
        • Epilepsy
        • Schizophrenia
        • Depression
        • ADHD
      • Respiratory
        • COPD
        • Asthma
        • Pulmonary Fibrosis
        • Cystic fibrosis
        • Rhinitis
      • Oncology
      • Diabetes
  • Careers
  • Contact Us
PHARMASCROLL
  • Home
  • About Us
    • Mission and Vision
    • Our Team
    • Why PharmaScroll
  • Business Intelligence
    • TreasureTell
  • Social Media Analytics
    • SocialBI
  • Market Research Services
  • Newsroom
    • Blog
    • Press Release
    • Recent News
      • Neuroscience
        • Migraine
        • Multiple Sclerosis
        • Alzheimer’s
        • Parkinson’s
        • Epilepsy
        • Schizophrenia
        • Depression
        • ADHD
      • Respiratory
        • COPD
        • Asthma
        • Pulmonary Fibrosis
        • Cystic fibrosis
        • Rhinitis
      • Oncology
      • Diabetes
  • Careers
  • Contact Us
enquiry@pharmascroll.com Mail Us
HomeNewsNeuroscienceDepression
  • FDA approves Alembic’s generic drug for Major Depressive Disorder

    • June 12, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • Esketamine displays positive Ph 3 trial outcomes for Depression

    • June 3, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • Allergan acquires depression compound from Aptinyx

    • May 24, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • 33 percent more people suffer from Depression as compared to 2013, new research finds

    • May 11, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • Esketamine improves outcomes in Treatment-Resistant Depression patients, new Phase 3 data shows

    • May 8, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • NDA submitted for Brexanolone in Postpartum Depression by Sage Therapeutics

    • April 24, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • Intranasal Esketamine improves Depression symptoms as per latest clinical trial results

    • April 21, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
Recent Posts
  • Unlocking the Benefits of SocialBI for Patient Engagement
  • Predictive Analytics in Healthcare
  • Business Intelligence and Analytics in the Pharma Industry
  • Role of Patient Insights in Building Strong Healthcare
  • Social Media Analytics in Healthcare

Contact Us

  • Indian Address: PharmaScroll Research and Consulting Private Limited, 91 Springboard, 4th floor, F948+W7, Laxmi Cyber City, Whitefields, Hyderabad, Telangana 500081
  • US address: 12 Self Ct, Wallingford CT 06492
  • +919311760222
  • enquiry@pharmascroll.com

Recent Tweets

  • Discover potential KOLs and explore the network maps of these KOLs with TreasureTell. Contact us for a demo: enqui… https://t.co/lC0jqVxxa02 days ago
  • The FDA has approved Tafinlar with Mekinist for the treatment of pediatric patients 1 year of age and older with lo… https://t.co/h5uRCFGRTl6 days ago

Recent Posts

  • Unlocking the Benefits of SocialBI for Patient Engagement
  • Predictive Analytics in Healthcare
  • Business Intelligence and Analytics in the Pharma Industry

News Letter

© 2023 Copyright. All rights reserved